Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7070, Idarubicin, and Cytarabine in Relapsed/Refractory AML and High-risk MDS
NCT01692197Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2013
- Primary completion
- Jun 2017
- Modality
- RNA-Targeting Small Molecules, Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of indisulam in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2013; status: completed.
02
Drugs
indisulam
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01692197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01692197.